Intellectual Property
Feb. 8, 2012
Generic drugmakers may challenge brand-name patents earlier under reform law
Under the patent reform law, generic drug manufacturers can challenge patents for new brand-name medicines much earlier than they have been able to in the past.
Daily Journal Staff Writer
Under the patent reform law passed last year, generic drug manufacturers can challenge patents for brand-name medicines much earlier than they have been able to in the past, possibly securing an attractive settlement or the right to make a cheaper drug faster.
The American Invents Act, which reformed patent laws, allows any third party to ask for a post-grant review or an inter partes review within n...
For only $95 a month (the price of 2 article purchases)
Receive unlimited article access and full access to our archives,
Daily Appellate Report, award winning columns, and our
Verdicts and Settlements.
Or
$795 for an entire year!
Or access this article for $45
(Purchase provides 7-day access to this article. Printing, posting or downloading is not allowed.)
Already a subscriber?
Sign In